ASCO Abstract Preview: ImClone, Genentech

---

Eli Lilly LLY:

Abstract No. 8011: Maintenance pemetrexed plus best supportive care vs. placebo plus BSC: A phase III study. Lung cancer.

---

Exelixis EXEL:

Abstract No. 3522: A phase I study of XL184, a RET, VEGFR2 and MET kinase inhibitor, in patients with advanced malignancies, including patients with medullary thyroid cancer.

Abstract No.8028: Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial.

Abstract No. 5103: A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients with papillary renal carcinoma.

Abstract No. 3510: A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients with advanced solid tumors.

---

Genentech DNA:

Abstract No. LBA1011: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO.

Abstract No. 2010b: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on six-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).

Abstract No. 4006: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab in the adjuvant treatment of patients with stage II/III colon cancer.

Abstract No. 8511: A phase I study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies.